找化学品上960化工网！
| 中文名称： | 卡利拉嗪 | 中文别名： | 卡利拉嗪 |
|---|---|---|---|
| 英文名称： | Cariprazine | CAS： | 839712-12-8 |
| 产品分类： | 小分子化合物 | 纯度： | ≥98% |
| 产品编号 | 品牌 | 纯度 | 规格 | 库存 | 价格 |
|---|---|---|---|---|---|
| IC6550 | 索莱宝 | ≥98% | 2mg | 有现货 | 780.00 元 |
| IC6550 | 索莱宝 | ≥98% | 1mg | 有现货 | 538.00 元 |
| IC6550 | 索莱宝 | ≥98% | 5mg | 有现货 | 990.00 元 |
| IC6550 | 索莱宝 | ≥98% | 10mg | 有现货 | 1,490.00 元 |
| IC6550 | 索莱宝 | ≥98% | 25mg | 有现货 | 2,932.00 元 |
| IC6550 | 索莱宝 | ≥98% | 50mg | 有现货 | 4,403.00 元 |
| 标准名称: | 卡利拉嗪 | 英文名称： | Cariprazine |
|---|---|---|---|
| CAS： | 839712-12-8 | 分子式： | C21H32Cl2N4O |
| 分子量： | 427.410983085632 | 颜色与性状： | |
| 密度： | 1.24 | 沸点： | |
| 熔点： | 水溶性： |
| CAS | 839712-12-8 |
| 中文名称 | 卡利拉嗪 |
| 英文名称 | Cariprazine |
| 别名 | RGH-188 |
| 分子式 | C21H32Cl2N4O |
| 分子量 | 427.41 |
| 规格 | 2mg ; 1mg ; 5mg ; 10mg ; 25mg ; 50mg |
| 溶解性 | Soluble in DMSO ≥0.1mg/mL(Need ultrasonic or Water bath) |
| 纯度 | ≥98% |
| 外观(性状) | White to brown Solid |
| 储存条件 | Powder:2-8℃，2 years |
| 运输条件 | 冷藏运输 |
| InChIKey | KPWSJANDNDDRMB-UHFFFAOYSA-N |
| 靶点 | Dopamine Receptor;5-HT1A |
| 通路 | Neuronal Signaling;GPCR & G Protein |
| 背景说明 | Cariprazine可以结合D3, D2 和 5-HT1A，可用于抗精神病方向的研究。 |
| 生物活性 | Cariprazine is a novel antipsychotic agent candidate that exhibits high affinity for the D3 (Ki=0.085 nM) and D2 (Ki=0.49 nM) receptors， and moderate affinity for the 5-HT1A receptor (Ki=2.6 nM).[1-4] |
| In Vitro | Cariprazine stimulates inositol phosphate (IP) formation with a high potency (pEC50 8.5) with relatively low efficacy (Emax 30%)[2]. Cariprazine， a novel candidate antipsychotic， demonstrated approximately 10-fold higher affinity for human D3 versus human D2L and human D2S receptors (pKi 10.07， 9.16， and 9.31， respectively). Cariprazine displays high affinity at human serotonin (5-HT) type 2B receptors (pKi 9.24) with pure antagonism. Cariprazine has lower affinity at human and rat hippocampal 5-HT1A receptors (pKi 8.59 and 8.34， respectively) and demonstrates low intrinsic efficacy. Cariprazine displays low affinity at human 5-HT2A receptors (pKi 7.73). Moderate or low affinity for histamine H1 and 5-HT2C receptors (pKi 7.63 and 6.87， respectively) suggest Cariprazines reduced propensity for adverse events related to these receptors[2]. Cariprazine is over sixfold more potent (EC50=1.4 nM) than Aripiprazole (EC50=9.2 nM) in inhibiting isoproterenol-induced cAMP production in HEK-293 cells[4]. |
| In Vivo | Administration of Cariprazine (30 μg/kg) reduces the striatal uptake of both radioligands to the level of nonspecific binding compared with baseline PET measurements. Cariprazine has negligible effect on the time-activity curves in the cerebellum. At doses of 5.0 and 30 μg/kg， Cariprazine causes a dose-dependent dopamine D2/D3 receptor occupancy of ~45% and ~80% for both antagonist [11C] raclopride and agonist radioligand [11C]MNPA. Receptor occupancy of dopamine D2/D3 receptors calculated using the transient equilibrium and the MRTM2 methods ranged from 5% at the lowest dose (1.0 μg/kg) to 94% at the highest dose (300 μg/kg)[1]. The effects of 5 doses of Cariprazine (ranging from 0.005 to 0.15 mg/kg) are examined on EPM behavior of wild-type mice. Whereas lower doses of Cariprazine (0.005 to 0.02 mg/kg) do not alter the time spent in open arms， the two higher doses (0.08 and 0.15 mg/kg) lead to a significant decline of this measure (ANOVA， (F(5，52)=4.20; p=0.0032)). Moreover， the two higher doses of Cariprazine also lead to a significant decrease in the total number of arm entries (F(5，52)=7.21; p=0.0001)) but this decrease in the total number of arm entries is largely accounted for by a significant decrease in the number of closed arm entries (F(5，52)=11.75; p=0.0001)). The two highest doses of Cariprazine (0.08 and 0.15 mg/kg) have significant effects on locomotor activity， but doses ranging from 0.005 to 0.02 mg/kg do not affect anxiety-like behavior or locomotor activity in the EPM test[3]. A significant (P[4]. |
| 细胞实验 | Cells are seeded on a 24-well tissue culture plate in 500 μL of medium. Fifty microliters of medium containing 0.55 μCi myo-[3H]inositol is added (final concentration 1 μCi/mL) and incubated for 18-20 h. Cells are then washed three times with buffer containing 140 mM NaCl， 5 mM KCl， 2 mM CaCl2， 5 mM HEPES， 5 mM Na-HEPES， 20 mM glucose， and 10 mM LiCl (pH 7.4). Cells are then incubated for an additional 60 min (37°C) in medium with test compounds alone (agonist test) or alongside 1000 nM (±)-Quinpirole (antagonist test). Medium is then aspirated off， cells are lysed by adding 400 μL of 0.1 M HCl/2 mM CaCl2， and supernatants are frozen at ?72°C. After thawing and centrifugation at 1000g for 10 min， 200 μL of each supernatant is loaded on 250 μL of AG1-X8 (formate form) anion exchange column. Effluent is discarded， and columns are washed twice in 1.5 mL of distilled water. IPs are eluted with 2.5 mL of 1 M ammonium formate/0.1 M formic acid directly into scintillation vials， 10 mL of Optiphase HiSafe 3 is added， and the radioactivity is determined in a TriCarb 4900 scintillation counter[2]. |
| 动物实验 | Mice[3] Experiments are performed on wild-type C57Bl/6J mice. In tests of cognitive functions， it is essential to employ concentrations of drugs that have no effects on emotional behavior and that do not impair locomotor activity. Whether Cariprazine (administered at a dose range of 0.005 to 0.15 mg/kg) is first tested affected the behavior of mice in the EPM， a test of anxiety-related behavior that is also critically dependent upon normal locomotor activity. Animals are exposed to an EPM apparatus designed for mice (leg height: 45 cm， arm length: 35 cm， lane width: 5 cm， wall height: 15 cm). Testing (under 100 lux lighting) is performed between 1 and 4 PM. Mice are placed in the center of the maze and their time spent in open arms and the number of closed and open arm entries during a 5 min test period is recorded. Measures of the time spent in open arms and the number of open arm entries served as a measure of anxiety-like behavior. The number of closed arm entries served as a measure of locomotor activity. Rats[4] Adult male Sprague-Dawley rats (150-300 g) are used. Cariprazine is dissolved in 0.9% saline and administered at 0.06， 0.25， 0.5， and 1.0 mg/kg via intraperitoneal (i.p.) injection 1 h before i.c.v. injection of ouabain and daily thereafter for 7 days. Open field activity is assessed immediately following the i.c.v. injection and again after 7 days (the activity is noted 10-14 h after the last i.p. injection of Cariprazine). |
| 激酶实验 | These assays are done in 50 mM Tris (pH 7.4)， 100 mM NaCl， 7 mM MgCl2， 1 mM EDTA， and 1 mM DTT. Assay tubes (final volume 250 μL) contain 50 μM (striatum and hippocampus) or 1 μM (D2 and D3 cell membrane) GDP， the ligand to be examined， and membrane suspension (250 μg tissue/tube for the striatum and hippocampus and 20 μg protein/tube for hD2 and hD3 membranes). Samples are preincubated for 10 min at 30°C. After the addition of 50 pM [35S]GTPγS， membranes are incubated for an additional 60 min at 30°C. Nonspecific binding is determined in the presence of 10 μM GTPγS; basal binding is determined in the presence of buffer only. The assay is terminated by rapid filtration through UniFilter GF/B using a harvester， and the membranes washed four times with 1 mL of ice-cold buffer. After drying (40°C for 1 h)， 40 μL of Microscint is added to the filters， and the bound radioactivity is determined by a TopCount NXT counter[2]. |
| 数据来源文献 | [1]. Seneca N， et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate， cariprazine (RGH-188)， in monkey brain measured using positron emission tomography. Psychopharmacology (Berl). 2011 Dec;218(3):579-8 [2]. Kiss B， et al. Cariprazine (RGH-188)， a dopamine D(3) receptor-preferring， D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther. 2010 Apr;333(1):328-40. [3]. Zimnisky R， et al. Cariprazine， a dopamine D(3)-receptor-preferring partial agonist， blocks phencyclidine-induced impairments of working memory， attention set-shifting， and recognition memory in the mouse. Psychopharmacology (Berl). 2013 Mar;226(1):91-100 [4]. Gao Y， et al. Cariprazine exerts antimanic properties and interferes with dopamine D2 receptor β-arrestin interactions. Pharmacol Res Perspect. 2015 Feb;3(1):e00073. |
| 单位 | 瓶 |
| 1mM-5mg | 11.6984mL |
| 1mM-1mg | 2.3397mL |
| 1mM-10mg | 23.3967mL |
| 5mM-1mg | 0.4679mL |
| 5mM-5mg | 2.3397mL |
| 5mM-10mg | 4.6793mL |
| 10mM-1mg | 0.234mL |
| 10mM-5mg | 1.1698mL |
| 10mM-10mg | 2.3397mL |
公司拥有一批专业的研发人员，我们专注于生物产品的不断完善和创新。产品覆盖面广，品质可靠。先后开发了涵盖分子生物学、细胞生物学、免疫学、生物医学等领域的多种试剂及试剂盒。同时，索莱宝公司提供各种常规生化试剂，库存常备产品多达10000多种，可随时为广大科研工作者提供各类专业试剂。在质量方面，索莱宝谨记公司信念：质量高于一切。所有研发的产品都设有严谨的生产流程，科学的质量检测方法和成熟的质量检测程序，我们恪守对每一位用户的承诺：用专业的态度做专业的品牌。同时，公司组建了一支专业的技术服务队伍，能够为科研工作者提供专业的技术服务。每一位购买索莱宝产品的用户都能够得到专业的咨询和完善的售后服务。
索莱宝公司坚持与国际接轨，注重和国际先进企业的合作与交流，并提供产品代理、市场咨询等多项服务。公司将一如既往与世界更多知名品牌合作，不断为广大生物科研工作者提供更优质的产品和服务。公司理念：“为科研服务，为生命尽责”。一个人能够走多远，取决于与谁同行。索莱宝公司期待与各同行精诚合作。
索莱宝诚招生物试剂研发人员，期待与广大同行精诚合作，为广大科研工作者提供优质的产品，高效的物流以及专业的售后服务。索莱宝感谢所有朋友的支持与帮助，您的支持是我们前进的动力和保障。让我们携手同行，共同创造美好的明天。
| 企业认证： | 已认证 | 企业性质： | 生产研发 |
|---|---|---|---|
| 主营产品： | 尿嘧啶-d4 ； 1，2-丙二醇-d6 ； (1S，2R，5R)-2-(羟甲基)-5-乙烯基奎宁环 ； 5-Androsten-3β-ol-17-one ethyleneketal ； 牛蒡子醇 B ； | 供货范围： | 试剂 |
| 产品目录： | 119719 | 品牌： | 索莱宝 |
| 纯度 | 品牌 | 规格 | 发货地 |
|---|---|---|---|
| ≥98% | 索莱宝 | 1mg | 北京 |
